Investor Presentation - First Six Months of 2021
39
Investor presentation First six months of 2021
Novo Nordisk®
Diabetes volume growth remains solid with 4% growth in a large
USD 52 billion diabetes market
The number of treated patients¹ is expected to
grow by 4% annually towards 2026
209m
CAGR: +4%
ILLUSTRATIVE
The diabetes realised value2 is expected to grow by
5% annually towards 2026
$
52bn
CAGR: +5%
.
ILLUSTRATIVE
Key trends in diabetes
Innovation focused on oral GLP-1
and combinations
Biosimilar competition and loss
of exclusivity
Diabetes technology with digital
health
2020
2026
Other OAD
DPP-4i
SGLT-2i
2020
GLP-1
Insulin
•
Patients outcome beyond
glucose control
Evolving payer dynamics and
market access hurdles
•
2026
Access and affordability of
medicine
1 Internal estimates; 2 Evaluate April 2021 (consensus forecast based on up to 6 external brokers; Insulin+GLP-1 products are included in the insulin group; DPP-4i+SGLT2i products are included in the SGLT2i group);
Note: GLP-1+basal insulin combination sales are included in insulin; Other OAD includes metformin, SU and TZDs. Growth rates are compound annual growth rates (CAGR).View entire presentation